Horizon Pharma

About

Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.

Northbrook,Illinois,United States
501 - 1000
https://www.horizontherapeutics.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $861.50M
Industries: Biopharma,Biotechnology,Health Care,Life Science,Medical,Pharmaceutical,Therapeutics
Founded date: Jan 1, 2005
Number Of Employee: 501 - 1000
Operating Status: Active
Stock Symbol: nasdaq:HZNP
Legal Name: HORIZON THERAPEUTICS INC

Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine.

Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

20

$4.95B

Horizon Pharma has raised a total of $4.95B in funding over 2 rounds. Their latest funding was raised on Aug 6, 2020 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Aug 6, 2020	Post-IPO Equity	$0.96B	—	—	—	Detail
Jul 11, 2019	Post-IPO Debt	$600M	—	—	—	Detail
Mar 6, 2019	Post-IPO Equity	$344.99M	—	—	—	Detail
Mar 4, 2019	Post-IPO Equity	$326.80M	—	—	—	Detail
Oct 20, 2016	Post-IPO Debt	$300M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

9

0

Horizon Pharma has made 9 investments. Their most recent investment was on Oct 3, 2022, when Golden raised $40M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Oct 3, 2022 Golden	Series B	$40M	Artificial Intelligence	—
Sep 19, 2022 Motion	Series A	$13M	Analytics	—
Sep 14, 2022 Fazz	Series C	$75M	Banking	—
Oct 1, 2018 Fazz	Series A	$21M	Banking	—
Apr 1, 2017 Brex	Series A	$7M	Banking	—

Investors

Number of Lead Investors

Number of Investors

3

10

Horizon Pharma is funded by 10 investors. Deepfield and Essex Woodlands Healthcare Partners are the most recent investors.

Investor Name	Lead Investor	Funding Round
Deepfield	Yes	Post-IPO Debt
Essex Woodlands Healthcare Partners	Yes	Series C
Scale Venture Partners	Yes	Series B
Citigroup Global Markets	—	Post-IPO Debt
Cowen and Company	—	Post-IPO Debt
Kreos Capital	—	Post-IPO Debt
Oxford Finance LLC	—	Post-IPO Debt
Silicon Valley Bank	—	Post-IPO Debt
Pequot Capital	—	Series C
Sutter Hill Ventures	—	Series C

Employee Profiles

Number of Employee Profiles

25

Horizon Pharma has 25 current employee profiles, including Executive Shao-Lee Lin

Executive

Executive

Employee

Employee

Executive

Acquisition

Horizon Pharma has acquired 7 organizations. Their most recent acquisition was Nitec Pharma AG on Apr 1, 2010. They acquired Nitec Pharma AG for 0.

Date Company Name	Industry	Acquisition Type	Price
Apr 1, 2010 Nitec Pharma AG	Biotechnology	merge	—	Detail
Mar 19, 2014 Vidara Therapeutics	Biotechnology	—	—	Detail
Mar 30, 2015 Hyperion Therapeutics	Biopharma	acquisition	$ 1.10B	Detail
Sep 12, 2016 Raptor Pharmaceuticals	Biopharma	acquisition	$ 800M	Detail
May 8, 2017 River Vision Development	Health Care	acquisition	$ 145M	Detail